Emergent BioSolutions Stock Hits New 52-Week Low (EBS)

NEW YORK ( TheStreet) -- Emergent BioSolutions Incorporated (NYSE: EBS) hit a new 52-week low Friday as it is currently trading at $14.89, below its previous 52-week low of $14.90 with 288,318 shares traded as of 3:59 p.m. ET. Average volume has been 174,300 shares over the past 30 days.

Emergent BioSolutions has a market cap of $616.2 million and is part of the health care sector and drugs industry. Shares are down 9.1% year to date as of the close of trading on Thursday.

Emergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and antibody therapeutics primarily in the United States, the United Kingdom, and Vietnam. The company operates in two segments, BioDefense and BioSciences. The company has a P/E ratio of 24.2, below the average drugs industry P/E ratio of 28.1 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Emergent BioSolutions as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. You can view the full Emergent BioSolutions Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.